TrialHaematologica2010

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.

Seok Jin Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.